Rifapentine is an entry and replication inhibitor against yellow fever virus both in vitro and in vivo
Xijing Qian, Bingan Wu, Hailin Tang, Zhenghan Luo, Zhenghao Xu, Songying Ouyang, Xiangliang Li, Jianfeng Xie, Zhigang Yi, Qibin Leng, Yan Liu, Zhongtian Qi, Ping Zhao
Abstract
and wild-type C57 mice. The antiviral effect in vivo is robust during both prophylactic intervention and therapeutic treatment, and the activity is superior to sofosbuvir, a previously reported YFV inhibitor in mice. Our data show that rifapentine may serve as an effective anti-YFV agent, providing promising prospects in the development of YFV pharmacotherapy.
Topics & Concepts
RifapentineVirologyVirusBiologyViral replicationIn vivoMedicineGeneticsPathologyMycobacterium tuberculosisTuberculosisLatent tuberculosisMosquito-borne diseases and controlViral Infections and VectorsMalaria Research and Control